OC-0293 TNT in rectal cancer: Final results of the CAO/ARO/AIO-12 randomized phase 2 trial
Emmanouil Fokas(Düsseldorf University Hospital), Claus Rödel(Goethe University Frankfurt), Simon Kirste(University of Freiburg), Bülent Polat(University of Würzburg), Wolf O. Bechstein(Unknown), Anca‐Ligia Grosu(University of Freiburg), G. Klautke, Ralf‐Dieter Hofheinz(University of Mannheim), Tim Friede(Universitätsmedizin Göttingen), Thomas Kuhnt(Leipzig University), Markus Flentje, M. Ghadimi, Rainer Fietkau(Friedrich-Alexander-Universität Erlangen-Nürnberg), Anke Schlenska‐Lange(Krankenhaus Barmherzige Brüder), C.-T. Germer, T. Brunner
Cited by 0
Related Papers
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial
|The Lancet|2008|1.9k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial
|The Lancet Oncology|2009|960